Haobo Pharmaceutical completed a $63 million Series B2 financing round.

36Kr learned that "Haobo Pharmaceutical" announced the completion of a $63 million Series B2 financing round. This round of financing was co-led by Qiming Venture Partners and industrial investment institutions, with the participation of multiple domestic investment institutions such as Hankang Capital, CDH VGC, Yuansheng Venture Capital, Sherpa Healthcare Partners, and Yuansheng Capital. The funds raised in this round will be mainly invested in the core development areas of Haobo Pharmaceutical, focusing on three major directions: First, to accelerate the clinical trial process of the company's core product, AHB - 137, an innovative antisense oligonucleotide (ASO) drug for the clinical cure of chronic hepatitis B; Second, to make early preparations for the commercialization and industrialization of AHB - 137; Third, to continuously expand the R & D of the company's innovative pipeline and strengthen the construction of professional teams both at home and abroad.